Natural Killer (NK) Cells Therapy Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments by DelveInsight

Natural Killer Cells Therapy pipeline constitutes 7+ key companies continuously working towards developing 8+ Natural Killer Cells Therapy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Natural Killer Cells Therapy Overview
Natural killer cells, also known as NK cells are a type of lymphocytes and are key components of the innate immune system. They are highly specific predators that play a major role in the host rejection of both tumors and viral infected cells. NK cells have cytotoxic small granules, which contain special proteins such as perfins and proteases, which are known as granzymes in their cytoplasm. Perforins form pores in the cell membrane of the target cell through which the granzymes and associated molecules induce apoptosis.

"Natural Killer Cells Therapy Pipeline Insight, 2022" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Natural Killer Cells Therapy Market.

The Natural Killer Cells Therapy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Natural Killer Cells Therapy Pipeline Report: https://www.delveinsight.com/report-store/natural-killer-nk-cell-lymphoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

• Companies across the globe are diligently working toward developing novel Natural Killer Cells Therapy treatment therapies with a considerable amount of success over the years. Natural Killer Cells Therapy Key players such as - ONK Therapeutics, Navrogen, Chimeric Therapeutics, Catamaran Bio, fate Therapeutics, Gamida-Cell, Artiva Biotherapeutics, Dragonfly therapeutics, Affimed, XNK Therapeutics, Glycostem, CELLID, SMT bio Co., Ltd., Innate Pharma, and others, are developing therapies for the Natural Killer Cells Therapy treatment
• Natural Killer Cells Therapy Emerging therapies such as - ONKT102, NAV-001, CHM 0201, CAT-179, FT516, GDA-201, AB 101, DF1001, AFM13, Evencaleucel, GTA002, BVAC-C, SMT-NK, Monalizumab, and others are expected to have a significant impact on the Natural Killer Cells Therapy market in the coming years.
• In June 2022, SMT bio Co., Ltd. Initiated a randomized, placebo-controlled, open-label,phase IIb clinical trial to evaluate the antitumor activity of combination therapy of SMT-NK and pembrolizumab vs. pembrolizumab monotherapy in patients with advanced Biliary Tract Cancer.
• In September 2021, Nektar Therapeutics announced it has entered into a new oncology clinical collaboration with MerckKGaA, Darmstadt, Germany and Pfizer Inc. to evaluate the maintenance regimen of NKTR-255, Nektar's interleukin-15 (IL15) receptor agonist, in combination with a velumab, a PD-L1 inhibitor, in patients with locally advanced or metastatic urothelial carcinoma (UC) in the Phase II JAVELIN Bladder Medley study.

Natural Killer Cells Therapy Pipeline Therapeutics Assessment
• Natural Killer Cells Therapy Assessment by Product Type
• Natural Killer Cells Therapy By Stage and Product Type
• Natural Killer Cells Therapy Assessment by Route of Administration
• Natural Killer Cells Therapy By Stage and Route of Administration
• Natural Killer Cells Therapy Assessment by Molecule Type
• Natural Killer Cells Therapy by Stage and Molecule Type

DelveInsight's Natural Killer Cells Therapy Report covers around 5+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Emerging Natural Killer Cells Therapy Drugs Under Different Phases of Clinical Development Include:
• ONKT102: ONK Therapeutics
• NAV-001: Navrogen
• CHM 0201: Chimeric Therapeutics
• CAT-179: Catamaran Bio
• FT516: fate Therapeutics
• GDA-201: Gamida-Cell
• AB 101: Artiva Biotherapeutics
• DF1001: Dragonfly therapeutics
• AFM13: Affimed
• Evencaleucel: XNK Therapeutics
• GTA002: Glycostem
• BVAC-C: CELLID
• SMT-NK: SMT bio Co., Ltd.
• Monalizumab: Innate Pharma

Natural Killer Cells Therapy Pipeline Analysis:
The Natural Killer Cells Therapy pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the Natural Killer Cells Therapy treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Natural Killer Cells Therapy Treatment.
• Natural Killer Cells Therapy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Natural Killer Cells Therapy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Natural Killer Cells Therapy market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Natural Killer Cells Therapy product details are provided in the report. Download the Natural Killer Cells Therapy pipeline report to learn more about the emerging Natural Killer Cells Therapy therapies at:
https://www.delveinsight.com/sample-request/natural-killer-nk-cell-lymphoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Natural Killer Cells Therapy Pipeline Market Drivers
• Increasing interest towards NK Cell Therapies among biotech and pharma companies • Increase in collaborations and acquisitions between companies
• Increase in clinical and pre-clinical research with positive results

Natural Killer Cells Therapy Pipeline Market Barriers
• Cumbersome preparation method of CAR NK cells
• Autologous NK cells cannot serve as an effective treatment modality for solid tumors

Get a Free Sample PDF Report to know more about Natural Killer Cells Therapy Pipeline Assessment- https://www.delveinsight.com/sample-request/natural-killer-nk-cell-lymphoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Scope of Natural Killer Cells Therapy Pipeline Drug Insight
• Coverage: Global
• Key Natural Killer Cells Therapy Companies: ONK Therapeutics, Navrogen, Chimeric Therapeutics, Catamaran Bio, fate Therapeutics, Gamida-Cell, Artiva Biotherapeutics, Dragonfly therapeutics, Affimed, XNK Therapeutics, Glycostem, CELLID, SMT bio Co., Ltd., Innate Pharma, and others
• Key Natural Killer Cells Therapy Therapies: ONKT102, NAV-001, CHM 0201, CAT-179, FT516, GDA-201, AB 101, DF1001, AFM13, Evencaleucel, GTA002, BVAC-C, SMT-NK, Monalizumab, and others
• Natural Killer Cells Therapy Therapeutic Assessment: Natural Killer Cells Therapy current marketed and Natural Killer Cells Therapy emerging therapies
• Natural Killer Cells Therapy Market Dynamics: Natural Killer Cells Therapy market drivers and Natural Killer Cells Therapy market barriers

Request for Sample PDF Report for Natural Killer Cells Therapy Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/natural-killer-nk-cell-lymphoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1 Natural Killer Cells Therapy Report Introduction
2 Natural Killer Cells Therapy Executive Summary
3 Natural Killer Cells Therapy Overview
4 Natural Killer Cells Therapy- Analytical Perspective In-depth Commercial Assessment
5 Natural Killer Cells Therapy Pipeline Therapeutics
6 Natural Killer Cells Therapy Late Stage Products (Phase II/III)
7 Natural Killer Cells Therapy Mid Stage Products (Phase II)
8 Natural Killer Cells Therapy Early Stage Products (Phase I)
9 Natural Killer Cells Therapy Preclinical Stage Products
10 Natural Killer Cells Therapy Therapeutics Assessment
11 Natural Killer Cells Therapy Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Natural Killer Cells Therapy Key Companies
14 Natural Killer Cells Therapy Key Products
15 Natural Killer Cells Therapy Unmet Needs
16 Natural Killer Cells Therapy Market Drivers and Barriers
17 Natural Killer Cells Therapy Future Perspectives and Conclusion
18 Natural Killer Cells Therapy Analyst Views
19 Appendix
20 About DelveInsight

Download Sample PDF Report to know more about Natural Killer Cells Therapy drugs and therapies- https://www.delveinsight.com/sample-request/natural-killer-nk-cell-lymphoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Latest Reports:
Ventricular Assist Devices Market https://www.delveinsight.com/report-store/ventricular-assist-devices-vad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

"DelveInsight's 'Ventricular Assist Devices (VAD) Market Insight, Competitive Landscape and Market Forecast - 2027' report delivers an in-depth understanding of Ventricular Assist Devices and the historical and forecasted Ventricular Assist Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vein Illumination Devices Market https://www.delveinsight.com/report-store/vein-illumination-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

DelveInsight's 'Vein Illumination Devices - Market Insight, Competitive Landscape and Market Forecast, 2027' report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Basal Cell Carcinoma (Basal Cell Epithelioma) Market
https://www.delveinsight.com/report-store/basal-cell-carcinoma-basal-cell-epithelioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

DelveInsight's "Basal Cell Carcinoma (Basal Cell Epithelioma) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Basal Cell Carcinoma (Basal Cell Epithelioma), historical and forecasted epidemiology as well as the Basal Cell Carcinoma (Basal Cell Epithelioma) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
https://www.delveinsight.com/consulting

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.